Inx-315
Web1 mrt. 2024 · INX-315-01 is a first-in-human, Phase 1/2 open-label, dose-escalation and dose-expansion study that will enroll patients with ER+/HER2- breast cancer that has progressed on a prior CDK4/6i regimen and patients with CCNE1-amplified solid tumors that have progressed on standard of care treatment. Web4 apr. 2024 · Led by Patrick Roberts, Pharm.D., Ph.D., Chief Executive Officer and Co-Founder, Incyclix Bio is a cell cycle control company advancing precision treatments that target the aberrant proliferation...
Inx-315
Did you know?
Web31 mrt. 2024 · 2024 revenue at $4.3M year, primarily from transaction fees, an increase in total revenue of 77 percent compared to 2024. 2024 net loss from operations of $16M. INX reports an annual net income of ... Web28 feb. 2024 · INX-315-01 is a first-in-human, Phase 1/2 open-label, dose-escalation and dose-expansion study that will enroll patients with ER+/HER2- breast cancer that has progressed on a prior CDK4/6i...
Web31 mrt. 2024 · RESEARCH TRIANGLE PARK, N.C., March 31, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle … WebThe Phase 1/2 first-in-human study (INX-315-01) will evaluate INX-315 in patients that have ER+/HER2- #breastcancer that has progressed on a prior CDK4/6i regimen and patients …
Web28 feb. 2024 · The Phase 1/2 first-in-human study (INX-315-01) will assess the safety, pharmacokinetics, and preliminary antitumor activity of INX-315 in patients with advanced/metastatic cancers, specifically ER+/HER2- breast cancer that has progressed on a prior CDK4/6i regimen and CCNE1-amplified solid tumors that have progressed on … Web28 feb. 2024 · The Phase 1/2 first-in-human study (INX-315-01) will assess the safety, pharmacokinetics, and preliminary antitumor activity of INX-315 in patients with …
WebIncyclix Bio 预计将启动 INX-315 在 CDK4/6 耐药和 Cyclin E 过度表达的癌症(包括乳腺癌和卵巢癌)中的概念验证 1/2 期研究。 “CDK2 是一种癌症靶点,具有巨大的治疗潜力,可 …
WebIncyclix Bio’s lead compound, INX-315, is a novel, potent and selective CDK2 with compelling pre-clinical efficacy and safety data. CDK2 is a known driver of abnormal … regal movie theater mallWeb28 feb. 2024 · 2024年2月28日,生物技术公司Incyclix Bio, LLC宣布美国食品药品监督管理局(FDA)已批准主要化合物INX-315的新药研究(IND)申请,INX-315是一种新型、强 … regal movie theater midwest cityWebFunds to support clinical development of INX-315, the company’s lead Cyclin-Dependent Kinase 2 inhibitor Sid Subramony, Ph.D., of Boxer Capital to join Incyclix Bio’s board of directors RESEARCH TRIANGLE PARK, N.C., March 31, 2024 (GLOBE NEWSWIRE) -- Incyclix Bio, LLC (formerly Arc Therapeutics, LLC), a next-generation cell cycle control … regal movie theater monthly passWeb28 feb. 2024 · INX-315-01 is a first-in-human, Phase 1/2 open-label, dose-escalation and dose-expansion study that will enroll patients with ER+/HER2- breast cancer that has … probation office in melbourneWeb31 mrt. 2024 · Incyclix said the financing will be used to support the clinical development of its lead compound, INX-315, a selective cyclin-dependent kinase 2 (CDK2) inhibitor that is nearing clinical stage.... probation office in madison wiWeb31 mrt. 2024 · The company, Incyclix Bio – based in Research Triangle Park and formerly known as Arc Therapeutics – plans to initiate a proof-of-concept phase 1 study of its lead … probation office in jacksonvilleWeb5 aug. 2024 · With an initial focus on developing a novel, potent, and selective inhibitor of CDK2 to treat patients whose tumors are insensitive to CDK4/6 inhibition, the founding scientific team at ARC Therapeutic is applying rational design and stringent screening criteria to select a candidate CDK2 inhibitor. regal movie theater moreno valley